Jones Financial Companies
ADCT icon

Jones Financial Companies’s ADC Therapeutics ADCT Stock Holding History

Jones Financial Companies’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.1K Hold
3,000
– – ﹤0.01% 3543
2025
Q4 		$10.6K Hold
3,000
– – ﹤0.01% 3193
2025
Q3 		$10.9K Hold
3,000
– – ﹤0.01% 3045
2025
Q2 		$8.13K Buy
+3,000
New +$6.31K ﹤0.01% 2950

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jones Financial Companies's ADCT Position: Q1 2026 in Review

Jones Financial Companies held its ADC Therapeutics (ADCT) position steady in Q1 2026 at 3,000 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3543.

Jones Financial Companies first reported a position in ADCT in Q2 2025 and has held it in 4 quarters since. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Jones Financial Companies held 3,000 shares of ADC Therapeutics worth $11.1K as of Q1 2026.
  • Jones Financial Companies left its ADC Therapeutics share count unchanged in Q1 2026.
  • ADC Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #3543 holding.
  • Jones Financial Companies first reported a position in ADC Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.